Share Price and Basic Stock Data
Last Updated: November 7, 2025, 7:05 pm
| PEG Ratio | -1.79 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Dipna Pharmachem Ltd operates in the pharmaceuticals industry, with a current market capitalization of ₹48.6 Cr and a share price of ₹20.2. The company reported a significant increase in sales, rising from ₹73 Cr in FY 2022 to ₹100 Cr in FY 2023, and further climbing to ₹164 Cr in FY 2024. However, sales projected for FY 2025 are expected to decline to ₹125 Cr. The operating profit margin (OPM) stood at 2% for FY 2023 and FY 2024, indicating a relatively low efficiency in converting sales into profits. The company recorded quarterly sales of ₹74 Cr in both Sep 2023 and Mar 2024. Notably, operational expenses also rose, impacting profitability, which remained stagnant at ₹1 Cr for several quarters. The cash conversion cycle (CCC) improved significantly to -20 days by FY 2025, suggesting enhanced efficiency in managing working capital. Overall, while revenue trends show growth over the past few years, the anticipated decline in FY 2025 raises concerns regarding future performance.
Profitability and Efficiency Metrics
Dipna Pharmachem Ltd’s profitability metrics reveal a challenging landscape. The net profit for FY 2023 was recorded at ₹1 Cr, with a net profit margin of 0.91%. This margin declined to 0.77% for FY 2025, reflecting struggles in maintaining profitability amidst rising expenses. The return on equity (ROE) stood at 2.55%, which is considerably low compared to typical industry standards, indicating that the company’s ability to generate returns for shareholders is limited. The interest coverage ratio (ICR) for FY 2025 was reported at 1.71x, suggesting that the company has just enough earnings to cover its interest obligations, but this leaves little room for financial flexibility. Additionally, operational efficiency is highlighted by a significant reduction in debtor days from 135 days in FY 2022 to 69 days in FY 2024, indicating improved collections. However, the inventory turnover ratio of 3.85x for FY 2025 suggests that inventory management may still need enhancement. Overall, profitability remains a concern, compounded by thin margins and rising costs.
Balance Sheet Strength and Financial Ratios
The balance sheet of Dipna Pharmachem Ltd reflects a cautious financial position. Total borrowings stood at ₹17 Cr for FY 2025, with a debt-to-equity ratio of 0.44x, indicating a moderate level of leverage. The company’s reserves increased from ₹2 Cr in FY 2022 to ₹14 Cr in FY 2025, which provides a buffer for future operations and potential investments. The current ratio was reported at 1.56x for FY 2025, suggesting that the company is in a position to meet its short-term liabilities comfortably. However, the price-to-book value (P/BV) ratio of 0.89x indicates that the stock is trading below its book value, which may imply market skepticism about future growth prospects. Furthermore, the interest coverage ratio of 1.71x indicates limited ability to cover interest expenses, which could pose a risk if profitability does not improve. Overall, while the balance sheet shows some strengths, the reliance on debt and the low P/BV ratio may raise concerns among investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dipna Pharmachem Ltd has undergone significant changes, with promoter holdings declining from 66.56% in September 2022 to 9.98% by March 2024. Conversely, public ownership rose from 33.45% to 90.02% during the same period, indicating a shift towards greater public participation. This transition may reflect a loss of confidence among promoters or a strategic decision to dilute holdings to attract more public investment. The number of shareholders increased from 1,110 in September 2022 to 1,807 by March 2024, suggesting growing interest in the stock. However, the presence of institutional investors remains negligible, as FIIs and DIIs are not reported, which could limit the stock’s liquidity and stability. The increased public shareholding may enhance governance and transparency, but the declining promoter stake may raise concerns regarding long-term strategic direction. Overall, the evolving shareholding structure presents both opportunities and challenges for investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Dipna Pharmachem Ltd faces several risks that could impact its future performance. The anticipated decline in sales to ₹125 Cr in FY 2025 raises concerns about sustainable growth, particularly given the company’s historically low profit margins. Furthermore, the reliance on debt, with a total borrowing of ₹17 Cr, poses a risk if profitability does not improve, as the interest coverage ratio is already at a modest level. On the other hand, the company’s improved cash conversion cycle and growing reserves provide some positive indicators for operational efficiency and financial stability. The shift in shareholding towards public investors may also enhance corporate governance. Overall, while there are strengths in operational improvements, significant risks remain, particularly concerning profitability and market confidence. The company must navigate these challenges effectively to ensure long-term viability and growth in the competitive pharmaceutical industry.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dipna Pharmachem Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 137 Cr. | 109 | 247/84.3 | 31.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,906 Cr. | 450 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.9 Cr. | 25.2 | 29.1/17.0 | 38.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,608.79 Cr | 1,177.38 | 55.86 | 198.43 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 44 | 49 | 74 | 74 | 90 | 91 | 34 |
| Expenses | 28 | 42 | 48 | 73 | 73 | 88 | 89 | 32 |
| Operating Profit | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 |
| OPM % | 3% | 3% | 2% | 2% | 2% | 2% | 2% | 6% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| Tax % | 25% | 26% | 26% | 27% | 27% | 21% | 26% | 34% |
| Net Profit | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
| EPS in Rs | 33.00 | 84.00 | 0.13 | 0.24 | 0.24 | 0.20 | 0.14 | 0.27 |
Last Updated: July 16, 2025, 10:10 am
Below is a detailed analysis of the quarterly data for Dipna Pharmachem Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Sep 2024) to 34.00 Cr., marking a decrease of 57.00 Cr..
- For Expenses, as of Mar 2025, the value is 32.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 89.00 Cr. (Sep 2024) to 32.00 Cr., marking a decrease of 57.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Sep 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Mar 2025, the value is 6.00%. The value appears strong and on an upward trend. It has increased from 2.00% (Sep 2024) to 6.00%, marking an increase of 4.00%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Interest, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Sep 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Mar 2025, the value is 34.00%. The value appears to be increasing, which may not be favorable. It has increased from 26.00% (Sep 2024) to 34.00%, marking an increase of 8.00%.
- For Net Profit, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Sep 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.27. The value appears strong and on an upward trend. It has increased from 0.14 (Sep 2024) to 0.27, marking an increase of 0.13.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:29 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 20 | 30 | 31 | 73 | 100 | 164 | 125 |
| Expenses | 16 | 20 | 30 | 31 | 71 | 98 | 161 | 121 |
| Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 |
| OPM % | 2% | 2% | 1% | 1% | 3% | 2% | 2% | 3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 |
| Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% | 32% |
| Net Profit | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| EPS in Rs | 6.00 | 3.00 | 6.00 | 2.00 | 117.00 | 0.37 | 0.45 | 0.40 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
Dipna Pharmachem Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 20% |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 74% |
| 3 Years: | -6% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 142% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 3:16 pm
Balance Sheet
Last Updated: July 25, 2025, 1:26 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 12 | 24 | 24 |
| Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 | 14 |
| Borrowings | 5 | 6 | 10 | 12 | 10 | 16 | 19 | 17 |
| Other Liabilities | 6 | 8 | 8 | 12 | 24 | 37 | 76 | 77 |
| Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 |
| Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 |
Below is a detailed analysis of the balance sheet data for Dipna Pharmachem Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 24.00 Cr..
- For Reserves, as of Mar 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2024) to 14.00 Cr., marking an increase of 1.00 Cr..
- For Borrowings, as of Mar 2025, the value is 17.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 19.00 Cr. (Mar 2024) to 17.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 77.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 76.00 Cr. (Mar 2024) to 77.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 132.00 Cr.. The value appears to be improving (decreasing). It has decreased from 133.00 Cr. (Mar 2024) to 132.00 Cr., marking a decrease of 1.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 132.00 Cr.. The value appears to be declining and may need further review. It has decreased from 133.00 Cr. (Mar 2024) to 132.00 Cr., marking a decrease of 1.00 Cr..
- For Total Assets, as of Mar 2025, the value is 132.00 Cr.. The value appears to be declining and may need further review. It has decreased from 133.00 Cr. (Mar 2024) to 132.00 Cr., marking a decrease of 1.00 Cr..
However, the Borrowings (17.00 Cr.) are higher than the Reserves (14.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -6.00 | -10.00 | -12.00 | -8.00 | -14.00 | -16.00 | -13.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | 69 | 135 |
| Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | 86 | 88 |
| Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 | 243 |
| Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | -17 | -20 |
| Working Capital Days | 3 | 6 | 44 | 47 | 37 | 108 | 80 | 137 |
| ROCE % | 8% | 5% | 3% | 17% | 9% | 7% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.41 | 0.45 | 260.55 | 333.40 | 6.91 |
| Diluted EPS (Rs.) | 0.41 | 0.45 | 260.55 | 333.40 | 6.91 |
| Cash EPS (Rs.) | 0.40 | 0.45 | 0.77 | 335.17 | 8.97 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.01 | 15.60 | 20.35 | 496.74 | 163.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.01 | 15.60 | 20.35 | 496.74 | 163.34 |
| Revenue From Operations / Share (Rs.) | 51.95 | 68.34 | 83.48 | 20787.26 | 8857.11 |
| PBDIT / Share (Rs.) | 1.43 | 1.43 | 1.96 | 644.23 | 118.66 |
| PBIT / Share (Rs.) | 1.43 | 1.42 | 1.95 | 642.46 | 116.60 |
| PBT / Share (Rs.) | 0.59 | 0.59 | 1.15 | 449.80 | 15.71 |
| Net Profit / Share (Rs.) | 0.40 | 0.45 | 0.76 | 333.40 | 6.91 |
| PBDIT Margin (%) | 2.75 | 2.08 | 2.35 | 3.09 | 1.33 |
| PBIT Margin (%) | 2.75 | 2.07 | 2.33 | 3.09 | 1.31 |
| PBT Margin (%) | 1.13 | 0.86 | 1.38 | 2.16 | 0.17 |
| Net Profit Margin (%) | 0.77 | 0.66 | 0.91 | 1.60 | 0.07 |
| Return on Networth / Equity (%) | 2.53 | 2.89 | 3.74 | 67.11 | 4.23 |
| Return on Capital Employeed (%) | 7.25 | 6.82 | 6.06 | 44.39 | 9.58 |
| Return On Assets (%) | 0.73 | 0.81 | 1.17 | 3.22 | 0.09 |
| Long Term Debt / Equity (X) | 0.23 | 0.33 | 0.58 | 1.91 | 6.44 |
| Total Debt / Equity (X) | 0.44 | 0.51 | 0.65 | 5.86 | 21.74 |
| Asset Turnover Ratio (%) | 0.94 | 1.56 | 1.76 | 2.38 | 1.43 |
| Current Ratio (X) | 1.56 | 1.60 | 1.99 | 1.16 | 1.21 |
| Quick Ratio (X) | 1.23 | 1.15 | 1.50 | 0.95 | 0.85 |
| Inventory Turnover Ratio (X) | 3.85 | 5.84 | 0.00 | 10.03 | 4.90 |
| Interest Coverage Ratio (X) | 1.71 | 1.72 | 2.46 | 3.34 | 1.18 |
| Interest Coverage Ratio (Post Tax) (X) | 1.48 | 1.54 | 1.95 | 2.73 | 1.07 |
| Enterprise Value (Cr.) | 51.18 | 28.22 | 25.24 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.40 | 0.17 | 0.25 | 0.00 | 0.00 |
| EV / EBITDA (X) | 14.85 | 8.22 | 10.74 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.13 | 0.15 | 0.00 | 0.00 |
| Price / BV (X) | 0.89 | 0.60 | 0.61 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.27 | 0.13 | 0.15 | 0.00 | 0.00 |
| EarningsYield | 0.02 | 0.04 | 0.06 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dipna Pharmachem Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 3. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 51.95. It has decreased from 68.34 (Mar 24) to 51.95, marking a decrease of 16.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 2. There is no change compared to the previous period (Mar 24) which recorded 1.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 1.43, marking an increase of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.59. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.59.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
- For PBDIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.08 (Mar 24) to 2.75, marking an increase of 0.67.
- For PBIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.07 (Mar 24) to 2.75, marking an increase of 0.68.
- For PBT Margin (%), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 10. It has increased from 0.86 (Mar 24) to 1.13, marking an increase of 0.27.
- For Net Profit Margin (%), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 5. It has increased from 0.66 (Mar 24) to 0.77, marking an increase of 0.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.53. This value is below the healthy minimum of 15. It has decreased from 2.89 (Mar 24) to 2.53, marking a decrease of 0.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.25. This value is below the healthy minimum of 10. It has increased from 6.82 (Mar 24) to 7.25, marking an increase of 0.43.
- For Return On Assets (%), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 24) to 0.73, marking a decrease of 0.08.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.33 (Mar 24) to 0.23, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.44, marking a decrease of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.94. It has decreased from 1.56 (Mar 24) to 0.94, marking a decrease of 0.62.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 1.60 (Mar 24) to 1.56, marking a decrease of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 1.23. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 1.23, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 4. It has decreased from 5.84 (Mar 24) to 3.85, marking a decrease of 1.99.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.71. This value is below the healthy minimum of 3. It has decreased from 1.72 (Mar 24) to 1.71, marking a decrease of 0.01.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 3. It has decreased from 1.54 (Mar 24) to 1.48, marking a decrease of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 51.18. It has increased from 28.22 (Mar 24) to 51.18, marking an increase of 22.96.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.17 (Mar 24) to 0.40, marking an increase of 0.23.
- For EV / EBITDA (X), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 8.22 (Mar 24) to 14.85, marking an increase of 6.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
- For Price / BV (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has increased from 0.60 (Mar 24) to 0.89, marking an increase of 0.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dipna Pharmachem Ltd:
- Net Profit Margin: 0.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.25% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.53% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.48
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.23
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 49.3 (Industry average Stock P/E: 55.86)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.44
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.77%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A/211, Siddhi Vinayak Complex, Ahmedabad Gujarat 380055 | info@dipnapharmachem.com http://www.dipnapharmachem.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Keyur Dipakkumar Shah | Managing Director |
| Ms. Dipna Keyur Shah | Non Executive Director |
| Mr. Nirav Soni | Non Executive Director |
| Mr. Nandish Shaileshbhai Jani | Independent Director |
| Mr. Parin Bhavsar | Independent Director |
FAQ
What is the intrinsic value of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd's intrinsic value (as of 07 November 2025) is 16.41 which is 17.54% lower the current market price of 19.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 47.8 Cr. market cap, FY2025-2026 high/low of 26.3/6.40, reserves of ₹14 Cr, and liabilities of 132 Cr.
What is the Market Cap of Dipna Pharmachem Ltd?
The Market Cap of Dipna Pharmachem Ltd is 47.8 Cr..
What is the current Stock Price of Dipna Pharmachem Ltd as on 07 November 2025?
The current stock price of Dipna Pharmachem Ltd as on 07 November 2025 is 19.9.
What is the High / Low of Dipna Pharmachem Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dipna Pharmachem Ltd stocks is 26.3/6.40.
What is the Stock P/E of Dipna Pharmachem Ltd?
The Stock P/E of Dipna Pharmachem Ltd is 49.3.
What is the Book Value of Dipna Pharmachem Ltd?
The Book Value of Dipna Pharmachem Ltd is 16.0.
What is the Dividend Yield of Dipna Pharmachem Ltd?
The Dividend Yield of Dipna Pharmachem Ltd is 0.00 %.
What is the ROCE of Dipna Pharmachem Ltd?
The ROCE of Dipna Pharmachem Ltd is 6.64 %.
What is the ROE of Dipna Pharmachem Ltd?
The ROE of Dipna Pharmachem Ltd is 2.55 %.
What is the Face Value of Dipna Pharmachem Ltd?
The Face Value of Dipna Pharmachem Ltd is 10.0.